PrimeraDx Appoints Albert A. Luderer to its Board of Directors
Published: Sep 22, 2011
MANSFIELD, Mass., Sept. 22, 2011 /PRNewswire/ -- PrimeraDx today announced that Albert Luderer has been appointed to its Board of Directors.
President and CEO Matthew McManus commented: "We are excited to have Al join our board at this pivotal time. We have just launched the ICEPlex System, which is the first molecular diagnostics system that is capable of high multiplex, multi-modal qPCR, and Al brings many years of experience in the commercialization of innovative products. Al's established track record of commercializing diagnostic technologies will provide PrimeraDx with great strategic vision as we bring personalized medicine to the clinic."
Dr. Luderer has over 30 years of leadership experience in diagnostics, therapeutics and research tools companies. He currently serves as CEO and Board Member at Integrated Diagnostics. Dr. Luderer has served as President, CEO, and Director at BioTrove (acquired by Life Technologies), CEO and Director of Light Sciences Inc, President and COO at bioMerieux Inc, VP of R&D and Business Development at Dianon Systems (now Lab Corp), VP of Technology Development and Support at Boehringer Mannheim (now Roche), and Head of Biomedical Research for Ciba Corning. Dr. Luderer earned a PhD from Rutgers University.
"I am very enthusiastic about PrimeraDx and the core technology behind the ICEPlex platform. The ability to both run a high multiplex reaction and receive a quantitative result is very timely," Commented Dr. Luderer. "I believe that PrimeraDx is positioned to lead the next generation of molecular diagnostics technology with their all-in-one well solution."
PrimeraDx is dedicated to the high growth field of molecular diagnostics. The Company has developed a unique platform for high-multiplex, quantitative, real-time PCR based on its proprietary STAR technology, implemented on the walk-away ICEPlex® instrument system. PrimeraDx is developing a broad range of applications in oncology, infectious disease, companion diagnostics and multiple non-clinical molecular markets, both through its own efforts and in collaboration with partners. The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation. The Company's website is: www.primeradx.com or www.multiplexpcr.com.
CONTACT: Andrew Bond, +1-508-618-2752, firstname.lastname@example.org